Research ArticleClinical Studies
Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects
RIIKKA-LIISA VUORINEN, NIINA PAUNU, TAINA TURPEENNIEMI-HUJANEN, TAINA REUNAMO, ANTTI JEKUNEN, VESA KATAJA, HARRI SINTONEN, TIMO PURMONEN and PIRKKO-LIISA KELLOKUMPU-LEHTINEN
Anticancer Research October 2019, 39 (10) 5559-5564; DOI: https://doi.org/10.21873/anticanres.13749
RIIKKA-LIISA VUORINEN
1Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland
2Department of Gynecology and Obstetrics, Tampere University Hospital, Tampere, Finland
NIINA PAUNU
3Department of Oncology, Tampere University Hospital, Tampere, Finland
TAINA TURPEENNIEMI-HUJANEN
4Department of Oncology, Medical Research Center, Oulu University Hospital, Cancer and Translational Research Unit, Oulu University, Oulu, Finland
TAINA REUNAMO
5Department of Oncology, Turku University Hospital, Turku, Finland
ANTTI JEKUNEN
6Department of Oncology, Vaasa Central Hospital, Turku University, Vaasa, Finland
VESA KATAJA
7Department of Oncology, Kuopio University Hospital and Central Finland Central Hospital, Kuopio, Finland
HARRI SINTONEN
8Department of Public Health, University of Helsinki, Helsinki, Finland
TIMO PURMONEN
9Oy Medfiles Ltd, Kuopio, Finland
PIRKKO-LIISA KELLOKUMPU-LEHTINEN
1Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland
3Department of Oncology, Tampere University Hospital, Tampere, Finland
In this issue
Anticancer Research
Vol. 39, Issue 10
October 2019
Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects
RIIKKA-LIISA VUORINEN, NIINA PAUNU, TAINA TURPEENNIEMI-HUJANEN, TAINA REUNAMO, ANTTI JEKUNEN, VESA KATAJA, HARRI SINTONEN, TIMO PURMONEN, PIRKKO-LIISA KELLOKUMPU-LEHTINEN
Anticancer Research Oct 2019, 39 (10) 5559-5564; DOI: 10.21873/anticanres.13749
Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects
RIIKKA-LIISA VUORINEN, NIINA PAUNU, TAINA TURPEENNIEMI-HUJANEN, TAINA REUNAMO, ANTTI JEKUNEN, VESA KATAJA, HARRI SINTONEN, TIMO PURMONEN, PIRKKO-LIISA KELLOKUMPU-LEHTINEN
Anticancer Research Oct 2019, 39 (10) 5559-5564; DOI: 10.21873/anticanres.13749
Jump to section
Related Articles
- No related articles found.
Cited By...
- Efficacy of Sunitinib in Patients With Favorable and Intermediate Risk Metastatic Renal Cell Carcinoma - Lithuanian National Cancer Institute Experience
- Gonadal Function in Male Patients With Metastatic Renal Cell Cancer Treated With Sunitinib
- G-Protein-coupled Estrogen Receptor 1 Agonist G-1 Perturbs Sunitinib Resistance-related Phosphoproteomic Signatures in Renal Cell Carcinoma
- Estimating the Lifespan of Elderly Patients With Cerebral Metastases from Kidney Cancer
- PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma
- Interval Between Cancer Diagnosis and Radiotherapy - An Independent Prognostic Factor of Survival in Patients Irradiated for Bone Metastases from Kidney Cancer
- Management of Patients With Metastatic Renal Cell Cancer and Bone Metastases